Adolor Corporation and GlaxoSmithKline Announce FDA Advisory Committee to Review Entereg(R) (alvimopan) for the Management of Postoperative Ileus (POI)

EXTON, Pa. & PHILADELPHIA--(BUSINESS WIRE)-- Adolor Corporation (Nasdaq:ADLR) and GlaxoSmithKline (NYSE:GSK) announced today that the Gastrointestinal Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) will review Adolor’s New Drug Application (NDA) for Entereg® (alvimopan) for the proposed indication of acceleration of time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis on January 23, 2008 from 8:00 AM to 5:00 PM. The meeting will take place at the Hilton Washington DC/Silver Spring, Maryland Ballroom in Silver Spring, Maryland.

MORE ON THIS TOPIC